Latest Breaking News On - Executive daniel hicklin - Page 1 : comparemela.com

By Dean Seal Shares of Werewolf Therapeutics shot higher after the company presented Phase 1 trial data establishing proof of mechanism for its lead clinical.

Daniel hicklinWerewolf therapeuticsExecutive daniel hicklinDean sealArticle normalBiotechnology servicesHealthcare life sciencesFinancial performanceShare price movement disruptionsNew products servicesResearch developmentCorporate industrial newsProducts servicesNew product service testingContent typesFactiva filters